01 Expansion of Long-Read and Comprehensive Genome Sequencing Long-read and whole-genome sequencing can improve the detection and interpretation of structural variants and other genomic features that may be difficult to resolve with narrower testing approaches. This development is expanding the technical capabilities of genomics across research and clinical workflows rather than focusing on AI-enabled interpretation. NHGRI continues to support development of novel sequencing technologies for research and clinical applications. In March 2025, a review of national genomics programs reported that initiatives such as Genomics England were advancing clinical applications of long-read whole-genome sequencing, including its use in cancer genomics.
02 Increasing Integration of Genomic Data With Clinical Health Information Genomics is increasingly being connected with clinical records and other health information to make genomic results more usable within routine healthcare workflows. National programs are developing structured data systems, interoperability approaches, and clinical interfaces that allow genomic information to be shared across laboratories, healthcare providers, and patients. This structural change is moving genomics from standalone testing toward integrated clinical information infrastructure. In June 2025, NHGRI proposed a Clinical Data Ecosystem for Genomics to develop standardized APIs and structured genomic-data sharing across laboratories, healthcare providers, and patients.
01 Expansion of Genomic Testing Across Disease Research and Clinical Care The genomics market is supported by the expanding use of genomic information across rare diseases, oncology, inherited conditions, pharmacogenomics, and disease-risk assessment. The growing evidence base for clinical utility is therefore creating demand beyond research-focused sequencing.
01 High Costs of Genomic Data Infrastructure and Interpretation The genomics market faces restraints from the substantial infrastructure and expertise required to store, analyze, interpret, and clinically integrate genomic information. Although sequencing costs have fallen considerably, the broader workflow still requires computational resources, variant interpretation, data management, and specialized personnel. These requirements can limit adoption where healthcare organizations lack sufficient genomic infrastructure or trained specialists.
01 Expansion of Population-Level Genomic Screening Population-scale genomic screening represents a distinct opportunity for expanding genomics beyond patients already suspected of having genetic disorders. National programs are increasingly evaluating the use of genomic information for screening healthy newborns and adults for inherited disease risks and other clinically actionable conditions. If clinical utility and cost-effectiveness are established, these programs could substantially broaden the addressable population for genomic testing.
01 Establishing Clinical Utility and Standardized Interpretation of Genomic Results A major challenge is determining which genomic findings are sufficiently validated to influence clinical decisions. Differences in clinical workflows, evidence standards, and interpretation practices can therefore slow the translation of genomic discoveries into established medical practice.
January 2026 Illumina, Inc. received U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement for its TruSight™ Oncology Comprehensive (TSO Comprehensive) genomic profiling test. The reimbursement expands patient access to comprehensive genomic testing and strengthens Illumina's precision oncology diagnostics portfolio.
January 2026 Genomics Ltd. launched the Mystra AI Platform, an artificial intelligence-powered platform designed to improve disease risk prediction using genomic data. The launch expands the company's precision medicine capabilities and supports healthcare providers and pharmaceutical companies with advanced genomic insights.
October 2025 GeneDx received FDA Breakthrough Device Designation for its ExomeDx® and GenomeDx® genomic sequencing tests for diagnosing patients with suspected rare genetic disorders. The designation is expected to accelerate regulatory review and broaden access to advanced genomic diagnostics.
May 2025 GeneDx completed the acquisition of Fabric Genomics, an AI-powered genomic interpretation company, following the agreement announced in April 2025. The acquisition enhances GeneDx's genomic analysis capabilities by integrating advanced artificial intelligence into clinical genome interpretation workflows.